+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Nedaplatin for Injection Market - Global Forecast 2025-2030- Product Image
Nedaplatin for Injection Market - Global Forecast 2025-2030- Product Image
Sale

Nedaplatin for Injection Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6138999
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Nedaplatin, a next-generation platinum-based chemotherapy agent, is transforming oncology treatment strategies for diverse cancer indications. With its distinctive safety profile and proven efficacy, Nedaplatin is increasingly recognized by senior decision-makers seeking to optimize clinical outcomes and operational resilience within the global pharmaceutical market.

Market Snapshot: Nedaplatin’s Strategic Value in Platinum-Based Oncology Therapeutics

The Nedaplatin injection market is advancing rapidly due to its ability to address unmet pharmacological needs in the contemporary oncology landscape. As an alternative to traditional cisplatin, Nedaplatin mitigates significant toxicities—especially nephrotoxicity and ototoxicity—without compromising antitumor activity. This competitive differential has generated momentum among pharmaceutical leaders and biotech innovators for broadening its deployment across esophageal, head and neck, lung, and ovarian cancer treatments. Heightened demand is further supported by breakthroughs in precision medicine, regulatory flexibility for combination approvals, and the integration of real-world evidence, all of which enable adaptable, patient-centric care models.

Scope & Segmentation: Comprehensive View of the Nedaplatin Market

This report offers an in-depth analysis, segmenting the Nedaplatin landscape by indication, treatment line, distribution channel, end user, patient type, dosage form, package type, and formulation type, as well as region.

  • Indications: Esophageal cancer, head and neck cancer, lung cancer, epithelial ovarian cancer, germ cell ovarian cancer, and stromal ovarian cancer.
  • Treatment Lines: First line (combination and monotherapy), second line (combination and monotherapy), third line, and fourth line and beyond.
  • Distribution Channels: Private hospital pharmacy, public hospital pharmacy, chain retail pharmacy, independent retail pharmacy, and online pharmacy platforms.
  • End Users: Ambulatory surgical centers, specialized cancer research institutes, clinics, and hospitals.
  • Patient Types: Adult and pediatric patient profiles with differentiated safety and efficacy requirements.
  • Dosage Forms: Concentrated solution, lyophilized powder, and prefilled syringe formats.
  • Package Types: Multi-dose vial, prefilled cartridge, and single-dose vial configurations.
  • Formulation Types: Controlled release and standard release pharmacokinetics.
  • Regions: Key sub-regions and countries span the Americas, Europe, Middle East, Africa, and Asia-Pacific, including both established and emerging pharmaceutical markets.
  • Key Companies: Shionogi & Co., Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Viatris Inc., Intas Pharmaceuticals Limited, and Sagent Pharmaceuticals, Inc.

Key Takeaways: Critical Insights for Senior Executives

  • Nedaplatin’s unique safety attributes expand eligible treatment populations compared to older platinum-based compounds.
  • Compatibility with multimodal and combination therapy regimens supports patient-centered approaches and the integration of targeted or immunotherapeutic agents.
  • Global adoption is influenced by local regulatory conditions, reimbursement environments, and healthcare infrastructure variability, especially across Americas, EMEA, and Asia-Pacific.
  • Innovation in formulation, including controlled release technologies, is enhancing patient compliance and reducing administrative burdens in clinical settings.
  • Contract manufacturing and supply partnerships are enabling quality assurance and scalable distribution—addressing both regulatory compliance and production continuity requirements.
  • Strategic alliances are accelerating clinical evaluation, while robust real-world evidence generation is reinforcing the value proposition for key patient segments.

Tariff Impact: U.S. Policy Developments and Supply Chain Strategy

New U.S. tariff measures introduced for 2025 impact the import costs of platinum-based compounds, affecting Nedaplatin manufacturers reliant on international raw materials. To mitigate risks, organizations are restructuring supply chains by diversifying supplier bases, considering regional manufacturing hubs, and seeking joint ventures for secure material access. Proactive engagement with trade authorities and industry centers supports the continued global availability of Nedaplatin and underpins long-term competitiveness.

Methodology & Data Sources

This executive summary integrates qualitative and quantitative primary data from expert interviews—including oncologists, clinical pharmacists, and payer representatives—with secondary research from peer-reviewed literature, trial registries, regulatory reports, and industry white papers. Cross-verification and expert panel review ensure analytical rigor and credibility throughout the report.

Why This Report Matters

  • Offers actionable insights for R&D investment, supply chain diversification, and formulary planning, with a focus on sustainable oncology innovation.
  • Equips stakeholders with data-driven strategies to navigate regulatory, policy, and regional market complexities amid growing demand for safe and effective platinum-based therapies.
  • Supports decision-making for corporate leadership aiming to expand therapeutic portfolios and reinforce competitive positioning in both mature and emerging pharmaceutical markets.

Conclusion

Nedaplatin’s evolving value proposition—rooted in differentiated safety, clinical versatility, and strategic adaptability—positions it as an important growth catalyst for senior pharmaceutical and biotech leaders navigating the future of oncology care.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of personalized dosing strategies for Nedaplatin injection to optimize treatment outcomes in oncology
5.2. Expansion of regional manufacturing capabilities to reduce supply chain disruptions for Nedaplatin for injection
5.3. Growing clinical evidence supporting combination therapies of Nedaplatin injection with immuno-oncology agents for enhanced efficacy
5.4. Increasing focus on cost-effectiveness analyses of Nedaplatin injection in resource-limited healthcare settings
5.5. Advances in formulation stability for Nedaplatin injection to extend shelf life and improve patient access
5.6. Regulatory harmonization efforts to accelerate global approvals of Nedaplatin for injection in emerging markets
5.7. Strategic partnerships between pharmaceutical companies and contract manufacturers to scale up Nedaplatin injection production
5.8. Shift toward biosimilar development pipelines challenging branded Nedaplatin injection market share and pricing
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Nedaplatin for Injection Market, by Indication
8.1. Introduction
8.2. Esophageal Cancer
8.3. Head And Neck Cancer
8.4. Lung Cancer
8.5. Ovarian Cancer
8.5.1. Epithelial
8.5.2. Germ Cell
8.5.3. Stromal
9. Nedaplatin for Injection Market, by Treatment Line
9.1. Introduction
9.2. First Line
9.2.1. Combination Therapy
9.2.2. Monotherapy
9.3. Fourth Line And Beyond
9.4. Second Line
9.4.1. Combination Therapy
9.4.2. Monotherapy
9.5. Third Line
10. Nedaplatin for Injection Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.2.1. Private Hospital Pharmacy
10.2.2. Public Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
10.4.1. Chain Pharmacy
10.4.2. Independent Pharmacy
11. Nedaplatin for Injection Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Cancer Research Institutes
11.4. Clinics
11.5. Hospitals
12. Nedaplatin for Injection Market, by Patient Type
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Nedaplatin for Injection Market, by Dosage Form
13.1. Introduction
13.2. Concentrated Solution
13.3. Lyophilized Powder
13.4. Prefilled Syringe
14. Nedaplatin for Injection Market, by Package Type
14.1. Introduction
14.2. Multi-Dose Vial
14.3. Prefilled Cartridge
14.4. Single-Dose Vial
15. Nedaplatin for Injection Market, by Formulation Type
15.1. Introduction
15.2. Controlled Release
15.3. Standard Release
16. Americas Nedaplatin for Injection Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa Nedaplatin for Injection Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific Nedaplatin for Injection Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Shionogi & Co., Ltd.
19.3.2. Teva Pharmaceutical Industries Ltd.
19.3.3. Sandoz International GmbH
19.3.4. Fresenius Kabi AG
19.3.5. Hikma Pharmaceuticals PLC
19.3.6. Dr. Reddy’s Laboratories Ltd.
19.3.7. Cipla Limited
19.3.8. Viatris Inc.
19.3.9. Intas Pharmaceuticals Limited
19.3.10. Sagent Pharmaceuticals, Inc.
20. Research AI21. Research Statistics22. Research Contacts23. Research Articles24. Appendix
List of Figures
FIGURE 1. NEDAPLATIN FOR INJECTION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC NEDAPLATIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC NEDAPLATIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. NEDAPLATIN FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. NEDAPLATIN FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 31. NEDAPLATIN FOR INJECTION MARKET: RESEARCHAI
FIGURE 32. NEDAPLATIN FOR INJECTION MARKET: RESEARCHSTATISTICS
FIGURE 33. NEDAPLATIN FOR INJECTION MARKET: RESEARCHCONTACTS
FIGURE 34. NEDAPLATIN FOR INJECTION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NEDAPLATIN FOR INJECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY ESOPHAGEAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY ESOPHAGEAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY EPITHELIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY EPITHELIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY GERM CELL, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY GERM CELL, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY STROMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY STROMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY CONCENTRATED SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY CONCENTRATED SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY MULTI-DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY MULTI-DOSE VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PREFILLED CARTRIDGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PREFILLED CARTRIDGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY SINGLE-DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY SINGLE-DOSE VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY STANDARD RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL NEDAPLATIN FOR INJECTION MARKET SIZE, BY STANDARD RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS NEDAPLATIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES NEDAPLATIN FOR INJECTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 163. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 166. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 167. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 168. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 169. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 170. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 171. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 172. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 173. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 176. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 177. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 178. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 179. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 182. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 183. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 184. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 185. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2018-2024 (USD MILLION)
TABLE 186. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2025-2030 (USD MILLION)
TABLE 187. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 188. CANADA NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 189. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 190. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 191. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 192. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 193. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 194. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 195. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 196. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 197. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 198. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 199. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 202. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 203. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 204. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 205. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 208. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 209. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 210. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 211. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2018-2024 (USD MILLION)
TABLE 212. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2025-2030 (USD MILLION)
TABLE 213. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 214. MEXICO NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY PACKAGE TYPE, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA NEDAPLATIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY FIRST LINE, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY SECOND LINE, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 311. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 314. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 315. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 316. UNITED KINGDOM NEDAPLATIN FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 202

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Nedaplatin for Injection Market report include:
  • Shionogi & Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy’s Laboratories Ltd.
  • Cipla Limited
  • Viatris Inc.
  • Intas Pharmaceuticals Limited
  • Sagent Pharmaceuticals, Inc.

Related Topics

Related Reports

Cadonilimab Injection Market - Global Forecast 2025-2030 - Product Image

Cadonilimab Injection Market - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Ipilimumab Injection Market - Global Forecast 2025-2030 - Product Image

Ipilimumab Injection Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Paclitaxel Injection Market Report 2025 - Product Image

Paclitaxel Injection Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Injection Pen Market Size, Share & Trends Analysis Report By Product (Disposable, Reusable), By Application (Osteoporosis, Diabetes, Anaphylaxis), By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Injection Pen Market Size, Share & Trends Analysis Report By Product (Disposable, Reusable), By Application (Osteoporosis, Diabetes, Anaphylaxis), By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 170 Pages
  • Global
From
Self-injection Devices Market Size, Share & Trends Analysis By Product (Auto Injectors, Pen Injectors), By Usability (Disposable, Reusable), By Application (Cancer, Autoimmune Disorders, Hormonal Disorders), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Self-injection Devices Market Size, Share & Trends Analysis By Product (Auto Injectors, Pen Injectors), By Usability (Disposable, Reusable), By Application (Cancer, Autoimmune Disorders, Hormonal Disorders), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.